EQS-News

Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis - Seite 3

The study was conducted at Hooke Laboratories, an independent full-service contract research organization with deep experience in the EAE animal model of MS.

At future international conferences, Pasithea plans to present its study data, including histology data and plasma inflammatory markers. The company will also submit complete data for peer-review publication.

For more information on Pasithea Therapeutics, visit www.pasithea.com.

Pasithea Therapeutics Corporation is a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Pasithea addresses the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

TraDigital IR- Camille Baptiste

[e-mail]

Company Website

https://www.pasithea.com/

News Source: News Direct

---

03.10.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---

Language:	English
Company:	Pasithea Therapeutics Corp.
	United States
ISIN:	US70261F1030
EQS News ID:	1455633

End of News	EQS News Service

1455633  03.10.2022 CET/CEST